NASDAQ: ENGNEngene Holdings Inc Stock
$5.40+0.25 (+4.85%)
Updated Mar 19, 2025
ENGN Price
$5.40
Fair Value Price
$0.45
Market Cap
$275.28M
52 Week Low
$4.42
52 Week High
$18.40
P/E
-3.55x
P/B
1.1x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$69.05M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$67M
Beta
0.1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENGN Overview
Forbion European Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets the life sciences industry in Europe. Forbion European Acquisition was incorporated in 2021 and is based in Wilmington, DE.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ENGN's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -9.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ENGN
Ranked#403 of 481
Ranked#403 of 481
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.25 | A | |
| $142.07 | A | |
| $1.55 | A |
Be the first to know about important ENGN news, forecast changes, insider trades & much more!
ENGN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ENGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENGN ($5.40) is overvalued by 1,092.05% relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ENGN ($5.40) is not significantly undervalued (1,092.05%) relative to our estimate of its Fair Value price of $0.45 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ENGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENGN due diligence checks available for Premium users.
Valuation
ENGN fair value
Fair Value of ENGN stock based on Discounted Cash Flow (DCF)
Price
$5.40
Fair Value
$0.45
Overvalued by
1,092.05%
ENGN ($5.40) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENGN ($5.40) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.55x
Industry
-113.22x
Market
31.13x
ENGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.1x
Industry
4.75x
ENGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.6M
Profit Margin
0%
ENGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$285.9M
Liabilities
$36.0M
Debt to equity
0.14
ENGN's short-term assets ($222.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENGN's short-term assets ($222.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.7M
Investing
-$85.0M
Financing
$1.0k
ENGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENGN vs Biotech Stocks
Engene Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.